Searchable abstracts of presentations at key conferences in endocrinology

ea0011p521 | Endocrine tumours and neoplasia | ECE2006

Outcome of management of craniopharyngiomas – a contemporary series

Rippin JD , Mitchell RD , McGregor EJ , Toogood AA , Gittoes NJ

The optimum management of patients with craniopharyngiomas is controversial. Evidence relies on a small number of retrospective outcome surveys that encompass time periods that are not necessarily representative of current surgical techniques and imaging modalities. We have reviewed outcome in a more contemporary group of patients managed at a single centre.Case-notes and electronic data were reviewed of all patients treated for craniopharyngioma since 1...

ea0007p9 | Bone | BES2004

Outcome of parathyroidectomy for primary hyperparathyroidism in 249 consecutive patients

Ma Y , Toogood A , Campbell D , Ready A , Gittoes N

Much has been written on the attributes of preoperative localisation and minimally invasive parathyroidectomy (MIP) for primary hyperparathyroidism. A recent 'summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century' (Bilezikian et al, 2002) suggested however that in experienced hands, conventional open parathyroidectomy with visualisation of all four glands was still the gold standard. In light of this we have carried o...

ea0005p168 | Growth and Development | BES2003

Differential regulation of the ghrelin promoter in WRL68 and HEK293 cells

Macartney D , Hughes B , Stewart P , Sheppard M , Toogood A

It is now evident that ghrelin is more than just a growth hormone (GH) secretagogue; it plays an important role in energy homeostasis, increasing food intake and fat deposition, has cardiovascular effects, and inhibits cell proliferation.Ghrelin mRNA expression is widespread in human tissues, but little is known about the molecular mechanisms and signals that regulate gene expression at the transcriptional level. To address this we cloned and sequenced a 4kb region upstrea...

ea0003oc12 | Endocrine Neoplasia | BES2002

Ghrelin inhibits proliferation of breast cell lines acting via the growth hormone secretagogue receptor (GHS-R)

Taylor J , Hughes B , Sheppard M , Stewart P , Toogood A

Ghrelin, the natural ligand for the GHS-R, modulates proliferation in cell lines derived from malignant breast tissue. It has been suggested that this action is independent of the GHS-R. We have previously demonstrated that MCF7 cells expressed ghrelin but not GHS-R mRNA and MDA-MB231 cells expressed GHS-R but not ghrelin mRNA. To determine whether ghrelin modulates proliferation in MCF7 and MDA-MB231 cells we performed proliferation assays treating with saline, 1 and 10nM ghr...

ea0003p204 | Neuroendocrinology | BES2002

Growth hormone (GH) deficiency in adults treated for acute lymphoblastic leukaemia (ALL) in childhood

Ayuk J , McGregor E , Mann J , Stewart P , Toogood A

The number of patients treated for malignant disease in childhood surviving into adulthood is increasing, but success is tempered by long-term side-effects of chemotherapy and radiotherapy; 40% develop one or more endocrinopathy. ALL is a common childhood malignancy treated with chemotherapy and cranial irradiation. The latter causes anterior pituitary hormone deficiencies, most frequently GH deficiency.We have determined GH status in 13 patients treate...

ea0075d19 | Diabetes | EYES2021

An usual case of hypoglycaemia

Coulden Amy , Ko Ye Lynn , Toogood Andrew , Ayuk John

A 69-year-old non-diabetic woman presented with 1 month of recurrent drowsiness and confusion secondary to hypoglycaemia, nocturnal and on fasting. On admission her CBG was 2.6 mmol/l, confirmed venously. Her history was of a large solitary fibrous tumour (SFT) of the chest wall first resected in 2011 with recurrent relapses requiring surgery in 2016 and 2017. Histology showed typical features of SFT. Despite palliative chemo-radiotherapy for a further relapses, there was prog...

ea0094p246 | Neuroendocrinology and Pituitary | SFEBES2023

Assessing growth hormone replacement practice in patients with hypopituitarism in queen elizabeth hospital birmingham

Sakthivel Pavithra , Wong Anson , Criseno Sherwin , Toogood Andrew

Background: In the UK, adults with growth hormone deficiency (GHD) are treated with recombinant Growth Hormone (GH) therapy according to NICE guidelines (TA64). Provided that patients show an initial improvement in their quality-of-life score, assessed using the Quality-of-Life Assessment of GHD in Adults (Qol-AGHDA) questionnaire, they can continue with their GH treatment long-term. However, in clinical practice, many patients are observed to discontinue GH r...

ea0050p283 | Neuroendocrinology and Pituitary | SFEBES2017

Impact of menopause on the natural history of pre-existing prolactinomas

Santharam Sandhya , Tampourlou Metaxia , Arlt Wiebke , Ayuk John , Gittoes Neil , Mtemererwa Brian , Toogood Andrew , Karavitaki Niki

Background: It has been proposed that menopause has a beneficial effect on the natural history of hyperprolactinaemia attributed to prolactinoma. Nonetheless, series systematically assessing outcome in females with prolactinoma who have passed through menopause are very limited.Aim: To investigate the impact of menopause on prolactinomas in patients not on dopamine agonist (DA) treatment.Patie...

ea0050p283 | Neuroendocrinology and Pituitary | SFEBES2017

Impact of menopause on the natural history of pre-existing prolactinomas

Santharam Sandhya , Tampourlou Metaxia , Arlt Wiebke , Ayuk John , Gittoes Neil , Mtemererwa Brian , Toogood Andrew , Karavitaki Niki

Background: It has been proposed that menopause has a beneficial effect on the natural history of hyperprolactinaemia attributed to prolactinoma. Nonetheless, series systematically assessing outcome in females with prolactinoma who have passed through menopause are very limited.Aim: To investigate the impact of menopause on prolactinomas in patients not on dopamine agonist (DA) treatment.Patie...

ea0090rc3.6 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Discontinuation of long-term growth hormone treatment in adults with severe growth hormone deficiency: A United Kingdom web-based survey of endocrine practice

Criseno Sherwin , Gleeson Helena , Toogood Andrew , Gittoes Neil , Topping Annie , Karavitaki Niki

Introduction: In adults, treatment of growth hormone deficiency (GHD) with daily recombinant human growth hormone (GH) injections has shown to improve many clinical features associated with GHD. Currently, many adults with GHD receive GH indefinitely, even when they fail to report any obvious benefits from this treatment. Additionally, evidence on the impact of discontinuing long-term GH therapy is limited. We conducted a survey of UK endocrine clinicians (doctors and speciali...